SCHEMBL5652996

SCHEMBL5652996

CN(C(=O)Oc1cccc2c1C(=O)OC2=O)c1ccccc1

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 3/20 0.51
LMNA P02545 2/20 0.51
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
RAB9A P51151 3/20 0.45
SMN1; SMN2 Q16637 3/20 0.45
NPC1 O15118 2/20 0.45
NPSR1 Q6W5P4 1/20 0.44
ALDH1A1 P00352 2/20 0.42
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
LIPE Q05469 2/20 0.38
TOP1 P11387 1/20 0.38
CHRNB2 P17787 1/20 0.37
CHRNB4 P30926 1/20 0.37
CHRNA3 P32297 1/20 0.37
CHRNA4 P43681 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11105481 0.82 L3MBTL1 (0.52) L3MBTL1LMNAMEN1KMT2ARAB9A
SCHEMBL2176042 0.76 KDM4E (0.50) L3MBTL1LMNAMEN1KMT2ASMN1; SMN2
SCHEMBL9680641 0.76 TOP1 (0.64) LMNAMEN1KMT2ASMN1; SMN2NPSR1
SCHEMBL5651828 0.75 L3MBTL1 (0.50) L3MBTL1LMNAMEN1KMT2ARAB9A
SCHEMBL25270459 0.73 L3MBTL1 (0.57) L3MBTL1LMNAMEN1KMT2ARAB9A
SCHEMBL5645492 0.73 L3MBTL1 (0.48) L3MBTL1LMNAMEN1KMT2ARAB9A
SCHEMBL11908091 0.73 ELANE (0.39) LMNAMEN1KMT2ARAB9ASMN1; SMN2
SCHEMBL27957751 0.73 POLM (0.46) LMNAMEN1KMT2AALDH1A1TOP1
SCHEMBL9663235 0.72 TDP1 (0.44) LMNAMEN1KMT2ARAB9ASMN1; SMN2
SCHEMBL25270735 0.71 RAB9A (0.55) L3MBTL1LMNAMEN1KMT2ARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030166644-A1 Compounds and uses thereof for decreasing activity of hormone-sensitive lipase NOVO NORDISK A/S (DK) 2003-09-04 US claimed
US-7279470-B2 Compounds and uses thereof for decreasing activity of hormone-sensitive lipase NOVO NORDISK A/S (DK) 2007-10-09 US disclosed
US-7067517-B2 Use of compounds for decreasing activity of hormone-sensitive lipase NERO NORDISK A/S (DK) 2006-06-27 US disclosed
US-20030166644-A1 Compounds and uses thereof for decreasing activity of hormone-sensitive lipase NOVO NORDISK A/S (DK) 2003-09-04 US disclosed
US-20030166690-A1 Use of compounds for decreasing activity of hormone-sensitive NOVO NORDISK A/S (DK) 2003-09-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030166644-A1 Compounds and uses thereof for decreasing activity of hormone-sensitive lipase LIPE, PNLIP, LPL L3MBTL1 1427/4885LMNA 1410/4885MEN1 2277/4885
US-20030166690-A1 Use of compounds for decreasing activity of hormone-sensitive LIPE, PNLIP, LPL L3MBTL1 2654/4885LMNA 2068/4885MEN1 1767/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.